Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tendon rupture in systemic lupus erythematosus.

R A Furie1, E K Chartash

  • 1Department of Medicine, North Shore University Hospital, Manhasset, NY 11030.

Seminars in Arthritis and Rheumatism
|November 1, 1988
PubMed
Summary

Tendon rupture is a rare but disabling complication of Systemic Lupus Erythematosus (SLE). Causes include trauma, inflammation from SLE, and corticosteroid use, requiring individualized treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod.

Lupus·2016
Same author

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Annals of the rheumatic diseases·2015
Same author

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.

Annals of the rheumatic diseases·2014
Same author

Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis.

Clinical and experimental rheumatology·2008
Same author

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study.

Annals of the rheumatic diseases·2005
Same author

Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients.

Lupus·2001

Area of Science:

  • Rheumatology
  • Immunology
  • Orthopedics

Background:

  • Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease.
  • Tendon complications, including rupture, are infrequent but significant in SLE patients.

Observation:

  • Tendon ruptures in SLE can occur due to trauma.
  • Inflammatory processes associated with SLE can affect tendons.
  • Corticosteroid therapy, often used in SLE management, is implicated in tendon weakening.

Findings:

  • The exact mechanisms leading to tendon rupture in SLE are not fully elucidated.
  • Both direct disease effects and iatrogenic factors contribute to tendon rupture risk.

Implications:

  • Understanding the multifactorial etiology is crucial for prevention and management.
  • Treatment strategies for SLE-related tendon rupture must be tailored to individual patient factors and rupture site.

Related Experiment Videos